Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Stock Down 2.6 %

Shares of AVXL stock opened at $8.47 on Friday. Anavex Life Sciences has a 12 month low of $3.25 and a 12 month high of $14.44. The business’s 50 day moving average is $9.94 and its two-hundred day moving average is $7.70. The company has a market cap of $718.43 million, a PE ratio of -16.29 and a beta of 0.69.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AVXL. HC Wainwright reissued a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 28th. D. Boral Capital restated a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Wednesday.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.